Security key
252828108
Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH)
CUSIP: 252828108
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 35,126,689
- Total 13F value
- $765,706,199
- Share change
- +2,962,012
- Put/Call ratio
- 150%
- SEC-reported price per share
- $21.80
- Number of holders
- 94
- Value change
- +$63,092,353
- Number of buys
- 47
- Number of sells
- 36
- Shares outstanding
- 54,752,594
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
94
Top holders
10
DNTH full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Dianthus Therapeutics, Inc. /DE/ SEC filings
Dianthus Therapeutics, Inc. /DE/ company facts
Broader feeds
Reporting periods
Holder history for CUSIP 252828108
Recent filing periods:
Ownership snapshot
Top reported holders of DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
30 Sep 2024
13F
3/4/5
Lead comparable stake: 8%
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
8%
Bain Capital Life Sciences Invest...
5.5%
Avidity Partners Management LP
5.3%
Fairmount Funds Management LLC
4.9%
RA CAPITAL MANAGEMENT, L.P.
4.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
Company
|
8%
|
$120,558,192
4,403,148 shares
|
— | 30 Sep 2024 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
5.5%
|
$82,507,522
3,013,423 shares
|
— | 30 Sep 2024 |
| Avidity Partners Management LP |
13F
Company
|
5.3%
|
$79,873,785
2,917,231 shares
|
— | 30 Sep 2024 |
| Fairmount Funds Management LLC |
13F
3/4/5
Company · Director
|
4.9%
|
$73,944,920
2,700,691 shares
|
— | 30 Sep 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
4.3%
|
$63,877,540
2,333,000 shares
|
— | 30 Sep 2024 |
| Octagon Capital Advisors LP |
13F
Company
|
3.2%
|
$47,823,742
1,746,667 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
94
Shares
35,126,689
Rows available
94
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
90
Q4 2024 holders
94
Holder diff
4
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend